AU2013309723B2 - N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug - Google Patents

N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug

Info

Publication number
AU2013309723B2
AU2013309723B2 AU2013309723A AU2013309723A AU2013309723B2 AU 2013309723 B2 AU2013309723 B2 AU 2013309723B2 AU 2013309723 A AU2013309723 A AU 2013309723A AU 2013309723 A AU2013309723 A AU 2013309723A AU 2013309723 B2 AU2013309723 B2 AU 2013309723B2
Authority
AU
Australia
Prior art keywords
acetohydrazide
indol
methylene
mmol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013309723A
Other languages
English (en)
Other versions
AU2013309723A1 (en
Inventor
Hojin Choi
Nina Ha
ChangGon LEE
Jaewon Lee
Song-Min Lee
Sunmi Lee
Su Kil Seo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Industry Academic Cooperation Foundation of Inje University
Original Assignee
Chong Kun Dang Corp
Industry Academic Cooperation Foundation of Inje University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp, Industry Academic Cooperation Foundation of Inje University filed Critical Chong Kun Dang Corp
Publication of AU2013309723A1 publication Critical patent/AU2013309723A1/en
Application granted granted Critical
Publication of AU2013309723B2 publication Critical patent/AU2013309723B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013309723A 2012-08-30 2013-08-29 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug Ceased AU2013309723B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20120095729 2012-08-30
KR10-2012-0095729 2012-08-30
KR20120108972 2012-09-28
KR10-2012-0108972 2012-09-28
PCT/KR2013/007751 WO2014035149A1 (en) 2012-08-30 2013-08-29 N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug

Publications (2)

Publication Number Publication Date
AU2013309723A1 AU2013309723A1 (en) 2015-02-26
AU2013309723B2 true AU2013309723B2 (en) 2016-07-14

Family

ID=50183887

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013309723A Ceased AU2013309723B2 (en) 2012-08-30 2013-08-29 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug

Country Status (15)

Country Link
US (1) US9447083B2 (enExample)
EP (1) EP2890677B1 (enExample)
JP (1) JP6139682B2 (enExample)
KR (1) KR101561987B1 (enExample)
CN (1) CN104755460B (enExample)
AU (1) AU2013309723B2 (enExample)
BR (1) BR112015004432A2 (enExample)
CA (1) CA2881797C (enExample)
ES (1) ES2651312T3 (enExample)
IN (1) IN2015MN00411A (enExample)
MX (1) MX368381B (enExample)
NZ (1) NZ704807A (enExample)
PH (1) PH12015500282B1 (enExample)
RU (1) RU2622651C2 (enExample)
WO (1) WO2014035149A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106986789B (zh) * 2016-01-20 2019-07-16 中国人民解放军军事医学科学院生物医学分析中心 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
EP3851519A4 (en) * 2018-09-28 2021-12-29 Nissan Chemical Corporation Additive for medium for promoting production of paracrine factor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
DE102004037515A1 (de) 2003-08-22 2005-03-17 Merck Patent Gmbh Verfahren zur Herstellung von Aldehyden
EP1885361A2 (en) * 2005-05-06 2008-02-13 Boehringer Ingelheim International GmbH Acyl hydrazones for treating cardiovascular diseases
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009155362A1 (en) * 2008-06-19 2009-12-23 Ligand Pharmaceuticals Inc. Small molecule hematopoietic growth factor mimetic compounds and their uses
WO2013032907A1 (en) 2011-08-26 2013-03-07 The Broad Institute, Inc. Compounds and methods for the treatment of cancer stem cells

Also Published As

Publication number Publication date
KR20140029318A (ko) 2014-03-10
JP6139682B2 (ja) 2017-05-31
PH12015500282A1 (en) 2015-04-27
KR101561987B1 (ko) 2015-10-20
EP2890677A4 (en) 2016-03-09
US9447083B2 (en) 2016-09-20
RU2015105511A (ru) 2016-10-20
PH12015500282B1 (en) 2015-04-27
CN104755460A (zh) 2015-07-01
MX2015002601A (es) 2015-09-29
EP2890677A1 (en) 2015-07-08
IN2015MN00411A (enExample) 2015-09-04
NZ704807A (en) 2016-06-24
CN104755460B (zh) 2017-05-10
RU2622651C2 (ru) 2017-06-19
BR112015004432A2 (pt) 2017-07-04
WO2014035149A1 (en) 2014-03-06
EP2890677B1 (en) 2017-11-15
MX368381B (es) 2019-09-30
CA2881797A1 (en) 2014-03-06
CA2881797C (en) 2017-08-01
AU2013309723A1 (en) 2015-02-26
ES2651312T3 (es) 2018-01-25
US20150252030A1 (en) 2015-09-10
JP2015526508A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
JP6231226B2 (ja) ピロリジン−２，５−ジオン誘導体、医薬組成物およびｉｄｏ１阻害剤としての使用のための方法
RU2584682C2 (ru) Индолил или индолинилгидроксаматные соединения, их содержащая фармацевтическая композиция (варианты) и способ лечения рака (варианты) с их помощью
JP2021534124A (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物
CA2726588C (en) Compounds and methods for treating inflammatory and fibrotic disorders
JP6615207B2 (ja) 複素環式化合物及びその使用
TW202342027A (zh) Prmt5-mta抑制劑
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
CA3090272A1 (en) Novel small molecule drug conjugates of gemcitabine derivatives
JP6831324B2 (ja) 特定のタンパク質キナーゼ阻害剤
WO2014116962A1 (en) Selective histone deacetylase 8 inhibitors
EP2890677B1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
WO2012036287A1 (ja) 新規コルチスタチンａ類似体およびその用途
RU2712140C2 (ru) Композиции для лечения фиброза и связанных с фиброзом состояний
JPH10175954A (ja) ４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
JP2020506879A (ja) 複素環式化合物及びその使用
CA3149302A1 (en) Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
JP7748392B2 (ja) 腫瘍微小環境における免疫調節のためのヒストンデアセチラーゼ阻害剤
RU2768451C1 (ru) Селективный антагонист рецепторов типа A2A
US11952328B2 (en) Selective ship inhibitors for treating disease
KR101459712B1 (ko) 야누스 키나아제 3을 활성을 선택적으로 저해하는 플라보노이드 유도체
EP4629986A1 (en) Treatment of graft-versus-host disease with inhibitors of bet family bdii bromodomain
TW202408991A (zh) Ido/tdo抑制劑
JP2006519845A (ja) キノロンカルボン酸誘導体を用いるガンの処置方法本特許出願は、２００３年３月７日に申請された米国暫定特許出願第６０／４５２，７７０号明細書への優先権を請求する。
JP2017214409A (ja) ピロリジン−２，５−ジオン誘導体、医薬組成物およびｉｄｏ１阻害剤としての使用のための方法
JP2014122171A (ja) アポトーシス抑制剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired